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Metastasis formation is a complex process and as such can only be modelled in vivo. As markers indicating metastatic spread in
syngenic mouse models differ significantly from those in man, this study aimed to develop a human melanoma xenograft mouse
model that reflects the clinical situation. Six human melanoma cell lines (LOX, MV3, FEMX-1, G361, MeWo and UISO-Mel6) were
xenografted into severe combined immunodeficient mice and tumour growth, metastatic behaviour and number of lung metastases
were assessed. Tumours and metastases were analysed for HPA binding and expression of CEACAM-1 and L1, all markers indicative
of metastasis in clinical studies. Development of primary tumour nodules ranged from 3 weeks (MV3) to 3 months (MeWo).
Whereas G361 and FEMX-1 rarely formed lung metastases, MeWo, MV3 and LOX were moderately and UISO-Mel6 was highly
metastatic. Similar to clinical studies, HPA, CEACAM1 and L1 indicated metastatic spread in the xenograft melanoma model, but
were not all simultaneously expressed in all cell lines. Considering the strongest expression of one marker combined with an absent
or low expression of the other two markers, we conclude that LOX is the cell line of choice for analyses of the functional role of
HPA-binding glycoconjugates, UISO-Mel6 is ideally suited to study CEACAM1 function in melanoma spread and L1 function can best
be modelled using MeWo.
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Malignant melanoma, being the most aggressive form of skin
cancer, represents a considerable clinical problem world-
wide, where about 1:35 Caucasians will suffer from malignant
melanoma during their lifetime with an incidence furthermore
accelerating (Lens and Dawes, 2004). If the primary melanoma can
be excised completely before it has spread to distant sites, the
patient is cured. However, if metastases occur the patient’s fate is
sealed, as in spite of intensive research no curative treatment is
yet available (Garbe and Blum, 2001; Eigentler et al, 2003). In
order to make progress in the field of metastasis treatment, the
process of malignant melanoma spread has to be better under-
stood. Metastasis formation is a complex process, which involves
many different steps, each of which has to be passed sequentially
in order to lead to a clinically detectable metastasis (Hart and
Saini, 1992). As this whole metastatic cascade is such a complex
process, simple in vitro experiments can only partially mimick the
course of metastatic spread and only animal experiments of
metastasis can represent the full picture of this multistep
phenomenon (Eccles, 2001).
In melanoma metastasis research, the mouse B16 melanoma
model has found widespread application (Tao et al, 1982). However,
as this model represents a syngenic mouse model, it suffers the
inherent problems of all murine models of metastasis, namely
whether it is directly transferable to humans. Concerning carbohy-
drate expression, which has profound influence on the metastatic
behaviour of tumour cells (Schumacher et al, 2005), murine B16
melanoma cells significantly differ from human melanoma cells.
Expression of WGA and PHA-L indicate metastatic spread of
murine B16 melanoma cells in mice (Tao et al, 1982); however, both
lectins were unable to predict metastatic spread in a clinical study
(Thies et al, 2001). A further disadvantage of murine melanoma
models is that murine melanocytes are exclusively located at the
papilla of the hair, whereas human melanocytes are additionally
found in the basal layer of the epidermis; thus, the biological
situation is different. A further disadvantage of the syngenic mouse
model is that all antibodies directed against human-specific antigens
are not applicable.
To overcome these problems, human tumour cells xenograft
animal model systems have been developed. In a number of
cancers, particularly in breast and colon cancers, human cancer
cell lines transplanted into severe combined immunodeficient
(scid) mice have resulted in model systems, which resemble the
clinical situation closely (Schumacher and Adam, 1997; Valentiner
et al, 2005).
During tumour metastasis, modulation of cell adhesion mole-
cule expression and aberrant glycosylation of the tumour cells play
a key role in the metastatic cascade. Simultaneously, in clinical
studies of malignant melanoma, binding of the lectin HPA
indicating aberrant glycosylation, and upregulation of the cell
adhesion molecules CEACAM1 and L1, have been correlated with
metastatic spread (Thies et al, 2001, 2002a,b).
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sThe aim of the present study was to investigate the metastatic
behaviour of human melanoma cells engrafted in scid mice. The
metastatic pattern of these cell lines were compared with markers
which have been useful to identify the metastatic phenotype of
malignant melanomas in clinical studies.
MATERIALS AND METHODS
Cell lines
The human melanoma cell lines UISO-Mel6 (established from a
primary malignant melanoma; see Rauth et al (1998)), MV3
(established from a metastatic melanoma lymph node; see Edward
(2001)) and MeWo (established from a metastatic melanoma
lymph node of a white, 78-year-old male; see Carey et al (1976))
were kindly provided by the Klinik fu ¨r Dermatologie, Universi-
ta ¨tsklinikum Hamburg-Eppendorf, Germany. The human melano-
ma cell lines LOX and FEMX-1 were both established from a
metastatic lymph node (Fodstad et al, 1988a,b). The human
melanoma cell line G361 (established from a primary malignant
melanoma from a 31-year-old Caucasian woman) was obtained
from the American Type Culture Collection (ATCC No. CRL-1424).
Cells were cultured under standard cell culture conditions (371C,
100% relative humidity, 5% CO2) in RPMI medium (Gibco, Paisley,
Scotland) supplemented with 10% heat-inactivated foetal
bovine serum (FBS, Gibco), 2mML -glutamine (Gibco), 100Uml
 1
penicillin and 100mlml
 1 streptomycin (Gibco). For injection, the
melanoma cells were harvested by trypsinisation, tested for
viability and were adjusted to a concentration of 5 10
6 viable
cells per 1ml cell culture. For glycoconjugate profiling of cell lines
in vitro, cells of each cell line were fixed in 4% neutral-buffered
formaldehyde and embedded in 4% agar before being processed to
paraffin wax.
Testing for mycoplasma infection
All cell lines were routinely tested for mycoplasma infection using
the PCR-based VenorGeM Mycoplasma Detection kit (Minerva
Biolabs GmbH, Berlin, Germany), following supplier’s instructions.
All cell lines were mycoplasma free.
Animals
The methodology for carrying out the animal experiments was
consistent with the UKCCR guidelines for the welfare of animals in
experimental neoplasia (Workman et al, 1997). The experiment
was recommended and supervised by the institutional animal
welfare officer, and the local licensing authority (Beho ¨rde fu ¨r
Soziales, Familie, Gesundheit, Verbraucherschutz; Amt fu ¨r
Gesundheit und Verbraucherschutz; Billstr. 80, D-20539 Hamburg,
Germany) approved the application for the experiment and
assigned the project No. F1/8/01.
Pathogen-free male balb/c severe combined immunodeficient
scid/scid mice aged 9–14 weeks were housed in filter-top cages
and were provided with sterile water and food ad libitum.
Mice weighed 20–25g at the beginning of the experiment. All
manipulations were carried out aseptically inside a laminar flow
hood. Mice were randomly grouped, with each group consisting of
10 animals for each cell line. 10
6 cells (in 200ml medium) were
injected subcutaneously between the scapulae of each scid mice.
The mice were killed when the tumour weight had reached 10% of
the weight of the mice or when the tumours started to ulcerate. For
duration of the experiment in each group, see Table 1a.
Histology
Mice were killed by cervical dislocation, and the tumours were
excised within their capsule, weighed and immediately fixed in 4%
neutral-buffered formalin. The lungs of all the animals were
dissected out and fixed in the same way for investigation of
the presence and number of lung metastases. Lungs were cut under
a dissecting microscope into 1-mm thick slices, which were spread
randomly over a glass slide and then embedded in 4% warm
liquefied agar. Slices were pressed down gently with a glass piston
to avoid floating of the slices within the agar during the cool down
process. The solidified agar blocks were then routinely processed
for wax histology. Paraffin blocks of the lungs were serially
sectioned. Numbers of lung metastases were analysed using the
simplified quantitative method standardised in our laboratory as
described by Jojovic and Schumacher (2000). Briefly, every 10th
section of each lung was retained and 10 sections from the middle
of the block were stained for H&E and the number of lung
Table 1 (a) Characteristics of six human melanoma cell lines xenografted into scid mice (n¼10 per cell line) and (b) glycoconjugate expression of their
respective primary tumours and spontaneous lung metastasis
Cell line Origin Duration (days) Mean tumour weight Metastasis rate (%) Mean number of lung metastases
(a)
G361 PT 40 0.93 30 75
FEMX-1 LNM 40 0.78 70
a 226
MeWo LNM 90 0.69 60 2860
MV3 LNM 20 1.13 80 196
LOX LNM 25 1.56 100 168
UISO-Mel6 PT 90 0.89 100 24031
Cell line L1 CEACAM1 bHPA IHPA WGA PHA-L
PT LM PT LM PT LM PT LM PT LM PT LM
(b)
G361 + + ++ ++ + + +++ +++ +++ +++   
FEMX-1 + + +++ + +/++ + + + +++ +   +
MeWo +++ +++ + + ++ ++ +/++/+++ ++/+++ +++ +++   
MV3 + +       + + +++ +++   
LOX + +    +++ +++ +++ +++ +++ +++   
UISO-Mel6 + +++ ++/+++ +++ + + + + +++ +++   
Cell lines are listed according to their metastatic potential from low to high.
aFEMX-1 developed only micrometastases, consisting of one to five cells. LNM¼lymph node
metastasis; PT¼primary tumour. Staining intensity was recorded as (–) negative, (+) weak, (++) moderate and (+++) intense. +: FEMX-1 developed only single-cell
micrometastases, which could not be evaluated immunohistochemically. PT¼primary tumour; LM¼lung metastasis.
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smetastases was counted at a  100 magnification. The mean value
of numbers of lung metastases in the 10 sections for each lung
(mean value10) was calculated. This mean value10 minus 20% was
multiplied by the total number of serial sections of the respective
lung in order to achieve an estimated value for the total number of
lung metastases. Furthermore, the anatomical site of lung
metastases (intravasal vs extravasal; pulmonary artery, bronchial
vessels and intraseptal veins) was recorded.
Lectin histochemistry
Paraffin sections (5mm) were processed for lectin- and immuno-
histochemistry using an avidin–biotin–alkaline phosphatase
staining technique as has been reported previously (Thies et al,
2001, 2002a,b).
Briefly, tissue sections were deparaffinised and rehydrated
through a series of graded ethanols. After pretreatment with
0.1% trypsin (type II, crude, from porcine pancreas, Sigma,
St Louis, MO, USA) in lectin buffer (0.05 M TRIS-buffered saline
pH 7.6, with 1mM CaCl2 and 1mM MgCl2 added), slides were
incubated sequentially with 10mgml
 1 biotinylated lectins (HPA,
WGA, PHA-L; Sigma, St Louis, MO, USA) for 1h at room
temperature. Slides were then incubated with an avidin–alkaline
phosphatase complex (Vectastain, Vector, ABC kit, Burlingame,
CA, USA) for 30min and enzyme reactivity of the alkaline
phosphatase complex was visualised using Naphtol-AS-bisphos-
phate as a substrate and hexatozised New Fuchsin was used for
simultaneous coupling. Slides were counterstained with Mayer’s
haemalum diluted 1:1 in distilled water for 10s, blued under
running tap water and mounted with Crystal Mount (Biomeda,
Foster City, CA, USA).
For HPA, an additional, indirect staining method, following
a standard protocol described earlier (Brooks et al, 1996) was
performed. The only variation to the described method by Brooks
et al (1996) was that the binding sites were visualised using an
alkaline phosphatase complex instead of a peroxidase complex
(Thies et al, 2001). Slides were pretreated as described above, but
were then incubated with native unconjugated HPA (10mgml
 1)
for 1h at room temperature. After an incubation with 10% normal
swine serum (DAKO, Glostrup, Denmark) for 30min, slides were
incubated overnight with a 1:100 diluted rabbit anti-HPA
antibody (EY Lab., San Mato, CA, USA) at 41C. Slides were then
incubated with a 1:300 diluted biotinylated swine anti-rabbit
antibody (DAKO, Glostrup, Denmark) for 30min, followed by
an incubation with a biotin–streptavidin–alkaline phosphatase
complex (Vectastain, Vector, ABC kit, Burlingame, CA, USA).
Developing enzyme reactivity, counterstaining and mounting was
performed as described above.
Negative controls were treated the same way as preincubating
the lectins with their respective nominal sugar. Serial sections of a
primary human cutaneous melanoma, which proved to intensively
bind the respective lectin in former studies (Thies et al, 2001)
served as appropriate positive control and for evaluation of
staining intensity.
Immuno-histochemistry
Details on the production and characterisation of the monoclonal
CEACAM1 antibody 4D1/C2 (in house preparation by Christoph
Wagener (CW)) and the polyclonal L1 antibody (L1-S; in house
preparation by Meliha Schachner (MS)) have been published
previously (Haspel et al, 2000).
For antigen retrieval, slides were either microwaved at 500W
five times for 2min in 10mmoll
 1 citrate buffer (pH 6.0),
(CEACAM1), or exposed to 0.015g protease (Sigma, Steinheim,
Germany) dissolved in 150ml TBS at 371C for 7min (L1).
Nonspecific binding was blocked by 10% normal rabbit serum
(CEACAM1) or 10% normal swine serum (L1). This was followed
by an overnight incubation with 4D1/C2 antibody at 8mgml
 1,o r
by the 1:100 diluted polyclonal rabbit anti-human L1 antibody.
Sections were then incubated with 1:40 diluted, biotinylated rabbit
anti-mouse (CEACAM1) or biotinylated swine anti-rabbit (L1)
antibody, followed by an incubation with an avidin–alkaline
phosphatase complex (Vectastain, Vector, ABC kit, Burlingame,
CA, USA) and antibody binding was visualised as described above.
Negative controls were treated the same way except replacing
the primary antibody by the isotype-matched IgG (CEACAM1:
Mouse IgG2a, k UPC-10; Sigma; L1: Mouse IgG1; NatuTec,
Frankfurt, Germany).
Central nervous myelin, as represented by an optic nerve,
further served as the appropriate negative control for L1 staining.
Cases of human primary malignant melanoma, which proved to
express the CEACAM1 and L1 molecules in former studies (Thies
et al, 2002a,b) served as appropriate positive controls and as a
standard for analysis of staining intensities. Additionally, for
L1-positive control, a human peripheral nerve was used.
Evaluation of staining pattern and statistical analyses
Two independent observers recorded the number of lung
metastases and staining of the melanoma cells in the sections of
primary tumours and lung metastases, which were encoded.
Additionally, the intensity of positive staining from weak (þ)t o
very intense staining (þþþ) was recorded. For documentation,
the slides were examined under a Zeiss Axioplan photomicroscope
and photographed digitally with a Zeiss MRc5 camera.
Correlation between the weight of the primary tumour and the
number of respective lung metastases was analysed with a two-
tailed Spearman rank correlation (Rko) using Graph Pad Prism 4.0
(Intuitive Software for Science, San Diego, CA, USA). Po0.05 was
regarded as statistically significant.
RESULTS
Tumour growth in scid mice, metastatic potential
and glycoconjugate expression
All six mycoplasma-free cell lines engrafted in scid mice
metastasised to the lungs; however, considerable variation
concerning their growth in scid mice, their metastatic potential
and glycoconjugate expression was observed (as summarised in
Table 1; cell lines are listed according to their metastatic potential
from low to high). Metastases of all six cell lines were located both
intravasal in either the pulmonary artery, bronchial vessels, or the
intraseptal veins and extravasal in the central or peripheral lung
tissue (Figure 1). In general, glycoconjugate expression in primary
tumour (PT) and corresponding spontaneous lung metastasis
(LM) was almost always identical.
G361
G361 cells developed primary tumours in all 10 scid mice, with an
end point tumour growth of 40 days and a mean tumour weight of
0.93g (range 0.4–1.4g). Only 3/10 animals developed spontaneous
lung metastases with a mean of only 75 metastases per lung (range
23–146). Primary tumours of six animals showed moderate
(þþ) CEACAM1 immunoreactivity and weak (þ) L1 immuno-
reactivity. G361 cells of PTs and LMs showed constant intense
(þþþ) iHPA binding and weak (þ) bHPA binding. In parallel
to the other five cell lines, G361 cells were intensively labelled with
WGA. No binding sites for PHA-L were observed in this cell line.
FEMX-I
FEMX-I developed primary tumours in all 10 scid mice, with an
end point tumour growth of 40 days and a mean tumour weight of
Clinically relevant melanoma model
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s0.78g (range 0.4–1.3g). Seven out of 10 animals developed
spontaneous lung metastases, with a mean of 226 metastases per
lung (range 240–480). FEMX-1 developed only micrometastases
consisting of one to five cells (Figure 2), which could not be
evaluated immuno-histochemically. This is in contrast to all other
cell lines, in which larger metastases had developed. Cells in the
PTs of all 10 animals showed homogenous intense (þþþ)
CEACAM1 immunoreactivity. L1 was weakly (þ) expressed in
the cells of 7/10 PTs. Cells in all PTs were homogenously labelled
with iHPA (þ) and bHPA (þ to þþ) and WGA (þþþ).
PHA-L bound to tumour cells in PTs of two animals.
MeWo
All 10 scid mice inoculated with MeWo cells developed primary
tumours, with an end point tumour growth of 90 days and a mean
tumour weight of 0.82g (range 0.3–1.3g). Six animals developed
spontaneous lung metastases with a mean of 2860 metastases per
lung (range 749–12168). MeWo primary tumours and lung
metastases showed equivocal intensity of glycoconjugate expres-
sion. Primary tumours and LMs were intensively (þþþ) L1-
positive (Figure 3) and weakly (þ) CAECAM1-positive. Lectin
histochemistry showed homogenous moderate (þþ) bHPA
binding. In contrast to the bHPA method, iHPA showed
heterogenous weak (þ) to intense (þþþ; PTs) or weak(þ)
to moderate (þþ) labelling of MeWo cells. WGA bound
intensively (þþþ) to MeWo cells in PTs and LMs. No PHA-L-
binding sites were observed.
MV3
All 10 scid mice inoculated with MV3 cells developed primary
tumours, with an end point tumour growth of 20 days and a mean
tumour weight of 1.13g (range 0.6–1.8g). Eight animals developed
spontaneous lung metastases with a mean of 196 metastases per
lung (range 19–672). In general, MV3 PTs) and LMs showed
homogenous glycoconjugate expression. Either all PTs and
LMs expressed the respective CAMs or bound the lectins or no
expression/binding was found. Staining intensities did not vary
between PTs and LMs. Primary tumours and lung metastases
expressed L1 (þ), whereas CEACAM1 was not expressed in either
PTs or LMs. Concerning lectin binding, PTs and LMs were weakly
(þ) labelled with iHPA but negative for bHPA. WGA-binding sites
were intensively (þþþ) expressed in all PTs and LMs.
LOX
Two of 10 animals inoculated with LOX cells died of unknown
reasons other than tumour growth. The remaining eight animals
developed PTs with an end point tumour growth of 25 days and a
mean tumour weight of 1.56g (range 0.6–2.4g). All eight animals
developed spontaneous lung metastases with a mean of 168
metastases per lung (range 33–355). Glycoconjugate expression in
PT and corresponding spontaneous lung metastasis was similar. LOX
cells expressed L1 (þ), but not did not express CEACAM1. Lectin
histochmistry revealed intense (þþþ) HPA labelling of all cells in
all PTs and LMs with both methods (Figure 4) and intense (þþþ)
WGA labelling. No binding sites for PHA-L were observed.
UISO-Mel6
All 10 scid mice inoculated with UISO-Mel6 cells developed
primary tumours, with an end point tumour growth of 90 days and
B
A
C
Figure 1 H&E staining of UISO-Mel6 lung metastasis. UISO-Mel6
developed lung metastases of enormous size (up to 900 cells in a cross-
section). (A) Metastasis in the pulmonary artery; (B) bronchial branch;
(C) extravasal melanoma cells. Bar represents 100mm.
Figure 2 H&E staining of FEMX-1 lung metastasis. FEMX-1 developed
only single-cell micrometastasis (arrow). Bar represents 100mm.
A
Figure 3 L1 immunohistochemistry of MeWo lung metastasis.
Melanoma cells show intense (þþþ) L1 immunoreactivity, and even
small metastases in the peripheral lung tissue are easy to detect (arrows).
(A) metastasis in the pulmonary artery. Bar represents 100mm.
Clinically relevant melanoma model
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sa mean tumour weight of 0.89g (range 0.1–1.5g). All 10 animals
developed spontaneous lung metastases of enormous size (up to
900 cells in a cross-section; Figure 1), with a mean of
24031 metastases per lung (range 10032–43668). UISO-Mel6
cells exhibited moderate (þþ) to intense (þþþ) CEACAM1
expression in 8/10 PTs (two PTs were negative for CEACAM1) and
intense (þþþ) CEACAM1 expression in the lung metastases of
all 10 animals (Figure 5). L1 was expressed in the cells of all 10 PTs
and in the cells of the lung metastases in all 10 animals. It was
striking to note that the intensity of L1 immunoreactivity was
significantly increased in the lung metastases (PTs: þ; LMs:
þþþ). Cells in 3/10 PTs and corresponding LMs were weakly
(þ) labelled with bHPA compared with the iHPA method, where
cells in 5/10 PT and cells of all LMs were weakly (þ) labelled. Cells
in all PTs and LMs were intensively (þþþ) labelled with WGA.
PHA-L-positive cells were recorded in the PT of one and in the
LMs of two animals.
Correlation between tumour weight and number of lung
metastases
No correlation between weight of the primary tumour and
numbers of spontaneous lung metastases existed for any of the
six cell lines (Table 2), and no critical tumour weight for metastasis
was apparent.
Glycoconjugate expression and immunoreactivity in vitro
compared with in vivo
Considerable differences between the glycoconjugate expression of
paraffin-embedded in vitro cell lines and the paraffin-embedded
in vivo tumours and metastases were obvious. Lectin histochemical
and immunohistochemical results of paraffin-embedded cell lines
in vitro are summarised in Table 3. All six cell lines expressed L1,
which is in parallel to the in vivo results, however, to considerably
different extents. CEACAM1 was only expressed by FEMX-1
(þþþ) and G361 (þþ), contrasting in vivo data, where UISO-
Mel6 (þþþ) and MeWo (þ) also showed CEACAM1 expres-
sion. HPA binding in vitro was comparable with that in vivo.
DISCUSSION
This study aimed at developing a clinically relevant melanoma
model. For this purpose, tumour growth and metastatic behaviour
of six different human melanoma cell lines subcutaneously
xenografted into scid mice was analysed and correlated with the
expression of proven markers of metastasis in clinical studies
(Thies et al, 2001, 2002a,b, 2006). The scid mouse was employed as
a host in the xenograft system as it has already proved useful as a
clinically relevant xenograft host for the metastatic spread of
A
B
Figure 4 Comparative HPA lectinhistochemistry using two different
methodological approaches. Primary tumours of the cell line LOX showed
intense (þþþ) membranous HPA labelling with both methods: (A)
bHPA using biotinylated HPA and (B) iHPA using native HPA and an anti-
HPA antibody. Bar represents 100mm.
B
A
Figure 5 CEACAM1 immunohistochemistry of an UISO-Mel6 lung
metastasis. The cells in the metastatic nodules exhibit intense (þþþ)
CEACAM1 immunoreactivity. Melanoma cells have invaded the lung tissue
starting from the (A) pulmonary artery. (B) Bronchial branch. Bar
represents 100mm.
Table 2 Correlation of tumour weight and number of lung metastasis of
human melanoma cell lines subcutaneously xenografted into scid mice
Cell line Spearman r 95% CI P
G361  0.18  0.75–0.55 0.65
FEMX-1 0.40  0.12–0.75 0.12
MeWo 0.61  0.03–0.89 0.06
LOX 0.04  0.69–0.72 0.94
MV3 0.30  0.40–0.78 0.39
UISO-Mel6  0.16  0.74–0.57 0.69
The number of lung metastases was not correlated with the weight of the primary
tumour in any of the six cell lines. CI¼confidence interval.
Clinically relevant melanoma model
A Thies et al
613
British Journal of Cancer (2007) 96(4), 609–616 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
shuman breast and colon cancer cell lines (Schumacher and Adam,
1997). Furthermore, subcutaneous injection of tumour cells, as
presented here, warrants that the metastatic cascade as a whole can
be analysed, whereas intravenous (iv) injection of tumour cells, as
sometimes described by others, results in dissemination rather
than in metastasis (Kjonniksen et al, 1994). For malignant
melanoma, in particular, subcutaneous injection has the advantage
of being an almost orthotopic model and therefore, reflects the
clinical situation from the anatomical point of view more closely
than the aforementioned iv injection. Considerable differences
between the glycoconjugate expression of in vitro grown cells and
the in vivo tumours resulting from the growth of injected cells and
their metastases in our study further underlines the considerable
importance of whole in vivo model systems for the study of
metastasis.
All cells from all six cell lines engrafted in scid mice, but as
expected, the time frame for the development of primary tumours
varied considerably between the cell lines, ranging from 3 weeks
(MV3) to 3 months (UISO-Mel6, MeWo). Somewhat surprisingly,
cells from all cell lines formed spontaneous metastases in the
lungs. However, no correlation between the metastatic rate and the
number of lung metastases was found, as has been described for
HT29 colon cancer cell lines and MDA MB 435 breast cancer cell
lines transplanted into scid mice (Schumacher and Adam 1997;
Valentiner et al, 2005). Furthermore, no threshold tumour weight
existed for any cell line, again contrasting with our results in colon
and breast cancer cell lines. However, this observation correlates
with the clinical situation of melanoma spread, as there are
patients presenting with thin melanomas at the time of surgery
who suffer from early metastasis and death whereas other patients
with thick melanomas survive (Balch et al, 2000).
UISO-Mel6 cells produced spontaneous lung metastases in all
animals and formed extremely high numbers of lung metastases,
and thus can be regarded as highly metastatic. Despite a 100%
metastatic rate, LOX cells formed only moderate numbers of lung
metastases in the mice, and MeWo cells produced high numbers of
lung metastases but metastasised in only 60% of the animals. MV3
cells formed moderate numbers of lung metastases and had a
metastatic rate of 80%. Hence, LOX, MeWo and MV are
intermediately metastatic. Although, FEMX-1 showed a metastatic
rate of 70%, it formed only few lung metastases and G361 rarely
metastasised to the lungs (metastatic rate 30%) and also developed
few numbers of metastases. These two cell lines can thus be
regarded as poorly metastatic.
FEMX-1, however, is so far particular with its metastatic pattern,
as FEMX-1 cells formed only micrometastases, consisting of one to
five cells, which therefore, could not be evaluated histochemically.
Primary tumours of FEMX-1 cells reached a size and weight
comparable to those of the other cell lines within a time frame of
90 days; therefore, micrometastases are not due to low tumour-
igenicity or short time-period. FEMX-1 xenografts might thus
present a model system to analyse melanoma dormancy, the
conceptual framework to explain a prolonged quiescence state
(beyond 10 years), in which tumour cells are present, but tumour
progression is not clinically apparent, as has been described in
approximately one-third of the melanoma patients (De Giorgi et al,
2003). To further analyse this hypothesis, metastatic behaviour of
FEMX-1 cells in mice after surgical excision of the primary tumour
should be analysed, which we are onto in our laboratory.
Correlating the metastatic behaviour of the six different human
melanoma cell lines in scid mice and their respective glycoconju-
gate expression, those markers indicating metastatic spread in
clinical studies (Thies et al, 2001, 2002a,b) were also indicative of
metastases in our xenograft model, and alike the clinical situation
(Thies et al, 2006), marker expression was conserved in the distant
metastases.
The highly metastatic cell line UISO-Mel6 broadly confirmed
that CEACAM1 is a marker of metastasis in the human melanoma
scid mouse model as well. Primary tumours and LMs of all animals
inoculated with UISO-Mel6 cells showed intense CEACAM1
expression and only low expression of the other markers. MeWo
and G361 PTs and LMs also expressed CEACAM1, however, to a
lower extent, and showed strong additional marker expression.
Therefore, UISO-Mel6 is the cell line of choice for analyses of
CEACAM1 function in melanoma metastasis.
In parallel to our clinical results (Thies et al, 2002b), all six cell
lines expressed L1 in the cells of all PTs and LMs, with MeWo
showing the most intense L1 expression. Strikingly, intensity of L1
immunoreactivity was even upregulated in UISO-Mel6 lung
metastases, which again reflects the clinical situation (Thies et al,
2006) and supports the hypothesis of a functional role of L1 in
melanoma metastasis. As a result of its intense L1 expression in
all PTs and LMs and its low expression of the other markers, the
cell line MeWo is ideally suited to further analyse L1 function in
melanoma metastasis.
HPA-binding glycoconjugates, having a well-established role in
cancer research (Schumacher et al, 2005), were expressed in five of
six tumorigenic and metastatic cell lines. In parallel to our clinical
investigation (Thies et al, 2002a), we compared two different
methodological approaches for HPA binding analyses, demon-
strating that in the animal model both methods are warranted.
LOX is the cell line of choice for study of the functional role of
HPA-binding carbohydrates in melanoma metastasis, as it shows
intense HPA binding, does not express CEACAM1 and shows only
low L1 expression. LOX further shows good tumour engraftment,
has a sizeable tumour grown within 25 days and a 100% metastasis
rate. Also, intensely HPA-positive and metastatic cell line MeWo
shows a tumour growth phase of 90 days, which has to be taken
into consideration, concerning therapeutic studies.
Kjonniksen et al (1994) demonstrated that the metastatic cell
line LOX showed strong HPA binding, which is in parallel to our
results. Additional results by that group showed, that the HPA-
negative cell line FEMX-1 was not metastatic after iv injection,
which is in contrast to our results, where all primary FEMX-1
tumours expressed HPA-binding sites and developed metastatic
deposits in the lungs of 7/10 mice. However, FEMX-1 metastases
frequently consisted of only one to five cells contrasting metastases
of the other cell lines. A simple explanation may, therefore, be that
these metastatic cells have been overlooked. A possible further
explanation is given by microbial contamination in this cell line.
We have established routine screening for mycoplasma, as about
30% of the permanent cell lines transferred to our facilities are
mycoplasma infected. Earlier xenograft experiments with FEMX-1
and MeWo (data not shown) showed that both cell lines were
Table 3 Comparative analysis of glycoconjugate expression of six human
melanoma cell lines in vitro (a) and in vivo (b)
Cell line L1 CEACAM-1 bHPA iHPA WGA PHA-L
(a) In vitro
G361 +++ ++ + + +++ +/++
FemX-I +++ +++ ++ + +++ ++
MeWo ++   + ++ +++ +
MV3 +    + +++ +++
LOX ++   +++ ++ +++ ++
UISO-Mel6 ++   + ++ +++  /+/++
(b) In vivo
G361 + ++ + +++ +++  
FemX-I + +++ +/++ + +++  
MeWo +++ + ++ +/++/+++ +++  
MV3 +    + +++  
LOX +   +++ +++ +++  
UISO-Mel6 + ++/+++ + + +++  
Expression of markers in vitro differed considerably from that of in vivo.
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sindeed less tumorigenic, did not metastasise into the lungs and
were HPA-negative, comparable to the results by Kjonniksen et al
(1994). They further did not express CEACAM1 (MeWo) and/or L1
(MeWo, FEMX-1). Subsequent tests for mycoplasma infection
demonstrated broad contamination of both cell lines with
mycoplasma. Our results presented here, using only mycoplasma
free cell lines, reversed these results, in part, and demonstrate
the considerable influence of mycoplasma contamination on the
carbohydrate expression, tumorigenic and metastatic potential
of tumour cells, as has also been reported by others (Uphoff
and Drexler, 2004). Therefore, stringent controls for and preven-
tion of mycoplasma contamination should be standard and
should be sought before any cell experiment proof of a
mycoplasma free-cell culture.
We furthermore analysed binding of the lectins PHA-L and
WGA, which indicated metastatic spread of murine B16 melanoma
cells (Tao et al, 1982), but are not correlated with melanoma
metastasis in man (Thies et al, 2001). In accordance to clinical
results, our human melanoma cell line xenograft model showed
no significance of PHA-L or WGA-binding glycoconjugates in
melanoma metastasis, and its clinical relevance is therefore
superior to that of the B16 melanoma model.
In parallel to clinical studies (Thies et al, 2006), not all markers
of metastatic spread were simultaneously expressed in all
metastatic cell lines, indicating the complexity of the metastatic
cascade and the heterogeneity of the tumour cells. The inherent
advantage of the model presented here is that because some cell
lines express all markers (UISO-Mel6; highest metastatic potential,
MeWO, G361) and others express only one or two markers, the
functional role of the respective carbohydrates can be analysed
alone and in combination with each other. CEACAM1, L1 and
HPA-binding carbohydrates (GalNAc/GlucNAc) might have multi-
ple function supporting melanoma metastasis, namely invasion
into and migration through the ECM as well as adhesion to the
endothelium and transendothelial migration or tumour vasculari-
sation (Ergu ¨n et al, 2000; Voura et al, 2001; Gutwein et al, 2003;
Ebrahimnejad et al, 2004; Schumacher et al, 2005), which can now
be analysed in our model system.
Besides their clinical relevance, these models own the advantage
that all human-specific antibodies can be used for preclinical
therapeutic studies, which are based upon recognition of human-
specific sequences.
Concluding, the human melanoma xenograft scid mouse model
presented in this study (i) closely reflects the clinical situation
and (ii) underlines the complexity of metastasis formation. It is
therefore, ideally suited to investigate the functional role of
CAMs and carbohydrates both separately and in combination with
each other.
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